A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients.

Trial Profile

A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Bronchiolitis obliterans
  • Focus Therapeutic Use
  • Acronyms EPOS
  • Most Recent Events

    • 08 Dec 2016 Planned End Date changed from 1 Jun 2017 to 1 Oct 2019.
    • 08 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2018.
    • 12 Apr 2016 According to European Clinical Trials Database, there has been an amendment in the severity of the disease from grade 1-2 to grade 1-3.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top